CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome
Phase of Trial: Phase II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs CER 001 (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms CARAT
- Sponsors Cerenis Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 30 Jan 2017 Status changed from active, no longer recruiting to completed.
- 19 Jan 2017 This trial has been completed in Hungary (end date: 30 Nov 2016).